- Trials with a EudraCT protocol (93)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
93 result(s) found for: Clear-cell adenocarcinoma.
Displaying page 1 of 5.
EudraCT Number: 2012-000473-23 | Sponsor Protocol Number: RETRY | Start Date*: 2012-05-29 | |||||||||||
Sponsor Name:GIOM - Gruppo Italiano Oncologia Nefrologica | |||||||||||||
Full Title: PHASE II STUDY OF SUNITINIB AS RECHALLENGE THIRD-LINE THERAPY IN METASTATIC RENAL CANCER | |||||||||||||
Medical condition: Metastatic renal cancer thrid-line therapy already treated in fist-line therapy with Sunitinib. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001337-13 | Sponsor Protocol Number: CRAD001LIC34T | Start Date*: 2012-08-17 | |||||||||||
Sponsor Name:APRO | |||||||||||||
Full Title: A randomized phase II study to explore the efficacy and feasibility of upfront rotations between sunitinib and everolimus versus sequential treatment of first line sunitinib and second line everoli... | |||||||||||||
Medical condition: Metastatic clear cell renal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000127-32 | Sponsor Protocol Number: ROPETAR | Start Date*: 2011-11-03 | |||||||||||||||||||||
Sponsor Name:Werkgroep Immunotherapie Nederland voor Oncologie | |||||||||||||||||||||||
Full Title: A randomized phase II study to explore the efficacy and feasibility of upfront bi-monthly rotations between Everolimus and Pazopanib with sequential treatment of first line Pazopanib and second lin... | |||||||||||||||||||||||
Medical condition: Advanced or metastatic clear cell renal cancer. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-004011-12 | Sponsor Protocol Number: SOGUG-2016-A-IEC(REN)-10 | Start Date*: 2017-03-29 | |||||||||||
Sponsor Name:SOGUG (Spanish Oncology Genitourinary Group) | |||||||||||||
Full Title: Phase II study to evaluate efficacy and safety of sunitinib therapy in patients with metastatic renal clear cell carcinoma who have progressed to first-line immunotherapy treatment (INMUNOSUN Study) | |||||||||||||
Medical condition: metastatic renal clear cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004699-38 | Sponsor Protocol Number: RCCC10 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Klinikum der Universität Regensburg | |||||||||||||
Full Title: A prospective phase I/II, one-arm, multi-center, open label study of pioglitazone in combination with sorafenib and low dose IFN alpha in metastatic, non-resectable renal clear cell carcinoma | |||||||||||||
Medical condition: To investigate the effect of an anti-inflammatory therapy consisting of pioglitazone (Actos) in combination with an angiostatic treatment with sorafenib (Nexavar) and Interferin-Alpha (Roferon) on ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019726-14 | Sponsor Protocol Number: CRO-2010-01 | Start Date*: 2010-09-20 | |||||||||||
Sponsor Name:CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO | |||||||||||||
Full Title: SORAFENIB IN ELDERLY PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (SERCC STIDY). IMPACT OF ADVERSE EVENTS MANAGEMENT IN ELDERLY mRCC PATIENTS TREATED WITH SORAFENIB. | |||||||||||||
Medical condition: PATIENTS WITH METASTATIC RENAL CELL CARCINOMA AGED >/= 65 YRS | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003054-28 | Sponsor Protocol Number: P070104 | Start Date*: 2007-10-17 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Etude des marqueurs biologiques, histologiques et d’imagerie dans le traitement de 1ère ligne du carcinome à cellules claires du rein en situation métastatique par Sunitinib avant et après néphrec... | |||||||||||||
Medical condition: Carcinome à cellules claires du rein en situation métastatique. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001211-31 | Sponsor Protocol Number: RG_10-177 | Start Date*: 2012-02-24 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and ECOG Performance Status 2 (PaZ02) | |||||||||||||
Medical condition: Clear cell renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002109-73 | Sponsor Protocol Number: NiCCC2013 | Start Date*: 2013-11-14 | ||||||||||||||||
Sponsor Name:Greater Glasgow Health Board | ||||||||||||||||||
Full Title: A Randomised Phase II Study of Nintedanib (BIBF1120) Compared to Chemotherapy in Patients with Recurrent Clear Cell Carcinoma of the Ovary or Endometrium | ||||||||||||||||||
Medical condition: Recurrent clear cell carcinoma of the ovary or endometrium | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: GB (Completed) FR (Completed) NL (Completed) DK (Prematurely Ended) FI (Prematurely Ended) NO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-000353-38 | Sponsor Protocol Number: WX-2003-07-HR | Start Date*: 2004-12-20 | |||||||||||
Sponsor Name:Wilex AG | |||||||||||||
Full Title: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence | |||||||||||||
Medical condition: Renal cell carcinoma of the clear cell type after nephrectomy and no evidence of residual disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) ES (Ongoing) GB (Completed) CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011669-10 | Sponsor Protocol Number: ARQ 197-204 | Start Date*: 2009-09-18 | |||||||||||||||||||||
Sponsor Name:ArQule, Inc. | |||||||||||||||||||||||
Full Title: A Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Associated Tumors | |||||||||||||||||||||||
Medical condition: Microphthalmia Transcription Factor Associated Tumors: Clear cell sarcoma Alveolar soft part sarcoma Translocation associated renal cell carcinoma (Renal cell ... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000706-12 | Sponsor Protocol Number: SUNNIFORECAST | Start Date*: 2017-01-23 | |||||||||||
Sponsor Name:Goethe University Frankfurt | |||||||||||||
Full Title: A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell ... | |||||||||||||
Medical condition: The primary objective of the study is to compare the of OS rate at 12 months of Nivolumab combined with Ipilimumab to Standard of Care in patients with previously untreated and advanced non-clear c... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Prematurely Ended) NL (Ongoing) CZ (Completed) BE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003779-36 | Sponsor Protocol Number: ICR-CTSU/2018/10066 | Start Date*: 2019-10-11 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:The Institute of Cancer Research | ||||||||||||||||||||||||||||||||||||||
Full Title: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss | ||||||||||||||||||||||||||||||||||||||
Medical condition: Relapsed ovarian and endometrial clear cell carcinoma or relapsed other gynaecological cancers (endometriod (ovarian and endometrial), carcinosarcoma (ovarian and endometrial), cerviacal carcinoma ... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005132-26 | Sponsor Protocol Number: CA209-025 | Start Date*: 2012-09-11 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Ther... | |||||||||||||||||||||||
Medical condition: Advanced or metastatic (medically or surgically unresectable) clear-cell Renal Cell Carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) FI (Completed) BE (Completed) DE (Completed) IT (Completed) AT (Completed) HU (Completed) CZ (Completed) DK (Completed) ES (Completed) NO (Completed) GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001246-13 | Sponsor Protocol Number: TV3/001/06 | Start Date*: 2007-01-22 |
Sponsor Name:Oxford BioMedica UK Ltd. | ||
Full Title: Estudio internacional, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos, para investigar si Trovax, añadido al tratamiento estándar de primera linea, prolonga la supervivenci... | ||
Medical condition: Locally advanced or metastatic renal clear cell adenocarcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) DE (Prematurely Ended) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-022459-45 | Sponsor Protocol Number: IMA901-301 | Start Date*: 2010-12-15 | ||||||||||||||||
Sponsor Name:immatics biotechnologies GmbH | ||||||||||||||||||
Full Title: A randomized, controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma | ||||||||||||||||||
Medical condition: The study population consists of HLA-A*02-positive metastatic and/or locally advanced RCC patients with histology of the clear-cell type who are aged 18 years or older and have a favorable or inter... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) HU (Completed) GB (Completed) NL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-005949-33 | Sponsor Protocol Number: Uni-Koeln-4316 | Start Date*: 2022-05-31 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: Prospective, single-arm trial of neoadjuvant nivolumab plus ipilimumab in patients with localized renal cell carcinoma who are at a high risk of relapse after radical nephrectomy (NEONIRenCa) | |||||||||||||
Medical condition: renal cell cancer (patients with locally advanced, non-metastatic renal cell cancer with dominant clear cell pathology) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000282-35 | Sponsor Protocol Number: BO17705 | Start Date*: 2004-09-29 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line tr... | |||||||||||||
Medical condition: Metastatic clear cell renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004502-34 | Sponsor Protocol Number: CA209-914 | Start Date*: 2017-08-11 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Parti... | |||||||||||||
Medical condition: Early stage localized Renal Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) BE (Completed) CZ (Completed) NL (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Ongoing) ES (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001030-19 | Sponsor Protocol Number: FP2CLI003 | Start Date*: 2021-06-14 | |||||||||||
Sponsor Name:Faron Pharmaceuticals Ltd | |||||||||||||
Full Title: A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma | |||||||||||||
Medical condition: -Localized clear cell renal cell cancer -Colon adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
